We are live on ! Find out more

AbCellera Biologics

ABCL

Market cap $3.7B

11.43 USD

-0.14

1.21%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

11.50

+0.07

0.61%

1 day

-1.21%

5 days

2.97%

1 month

87.68%

3 months

79.43%

6 months

214.88%

Year to date

233.24%

1 year

174.76%

5 years

-39.68%

10 years

-80.59%

About: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Employees: 562

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 47.1%

Neutral 47.1%

Negative 5.9%

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.

What'sGoing On With AbCellera Biologics Stock On Tuesday?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

New data show a single dose of AbCellera's menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

See News Rankings

Price charts implemented using Lightweight Charts™